ProCE Banner Activity

An Expert Video Roundtable on Novel Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Explore new treatment options and clinical challenges in blastic plasmacytoid dendritic cell neoplasm in this expert discussion with distinguished experts Roberto Lemoli, MD; Eric Deconinck, MD, PhD; and Daniel Wiseman, MB ChB, PhD.

Released: March 10, 2020

Expiration: March 09, 2021

No longer available for credit.

Share

Faculty

Eric Deconinck

Eric Deconinck, MD, PhD

Professor of Hematology
Université de Franche-Comté
Head, Hematology Department
Cancerology
Chu Besançon
Besançon, France

Roberto Lemoli

Roberto Lemoli, MD

Professor of Hematology
Department of Internal Medicine (Di.M.I.)
University of Genoa
Director, Clinic of Hematology
San Martino Hospital IRCCS
Genoa, Italy

Daniel Wiseman

Daniel Wiseman, MB ChB, PhD

Senior Leukaemia Research Fellow
Division of Cancer Sciences
The University of Manchester
Consultant Haematologist
Department of Haematology
The Christie NHS Foundation Trust
Manchester, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Stemline Therapeutics

Target Audience

This program is intended for global hematologists, medical oncologists, pathologists, and other healthcare providers who care for patients with hematologic malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop strategies for the rapid and accurate diagnosis of patients with suspected cases of blastic plasmacytoid dendritic cell neoplasm
  • Integrate recently approved and emerging treatment options into therapeutic strategies for patients with blastic plasmacytoid dendritic cell neoplasm

Faculty Disclosure

Primary Author

Eric Deconinck, MD, PhD

Professor of Hematology
Université de Franche-Comté
Head, Hematology Department
Cancerology
Chu Besançon
Besançon, France

Eric Deconinck, MD, PhD, has no relevant conflicts of interest to report.

Roberto Lemoli, MD

Professor of Hematology
Department of Internal Medicine (Di.M.I.)
University of Genoa
Director, Clinic of Hematology
San Martino Hospital IRCCS
Genoa, Italy

Roberto Lemoli, MD, has no relevant conflicts of interest to report.

Daniel Wiseman, MB ChB, PhD

Senior Leukaemia Research Fellow
Division of Cancer Sciences
The University of Manchester
Consultant Haematologist
Department of Haematology
The Christie NHS Foundation Trust
Manchester, United Kingdom

Daniel Wiseman, MB ChB, PhD, has no relevant conflicts of interest to report.

Staff Disclosure

Staff

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology


Timothy A. Quill, PhD

Senior Managing Editor


Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.

Additional Information

Program Medium

This program has been made available online.

Participation in this self-study activity should be completed in approximately hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 10, 2020, through March 09, 2021:

1. Register online at httpProgram Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in implementing strategies to screen, diagnose, and cure diverse populations of individuals infected with HCV in the United States.

Goal


The goal of this activity is to improve the knowledge and competence of global learners to apply practice-changing clinical data and expert recommendations to optimize the care of patients with blastic plasmacytoid dendritic cell neoplasm.